Ro 8-4304 hydrochloride

Discontinued Product

3343 has been discontinued.

View all NMDA Receptors products.
说明: GluN2B-selective NMDA antagonist
化学名: 4-[3-[4-(4-Fluorophenyl)-1,2,3,6-tetrahydro-1(2H)-pyridinyl]-2-hydroxypropoxy]benzamide hydrochloride
纯度: ≥99% (HPLC)
说明书
引用文献
评论
文献 (5)

生物活性 for Ro 8-4304 hydrochloride

NMDA receptor antagonist (IC50 = 0.4 μM) that displays > 100 fold selectivity for GluN2B (formally NR2B) containing receptors over GluN2A (formally NR2A) containing receptors. Exhibits an activity-dependent mechanism of NMDA antagonism and is competitive with respect to spermine (Cat. No. 0958).

Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.

技术数据 for Ro 8-4304 hydrochloride

分子量 406.88
公式 C21H23FN2O3.HCl
储存 Desiccate at RT
纯度 ≥99% (HPLC)
CAS Number 1312991-77-7
PubChem ID 11957680
InChI Key MQOXWHKUQOFFJW-UHFFFAOYSA-N
Smiles NC(C1=CC=C(OCC(O)CN2CCC(C3=CC=C(F)C=C3)=CC2)C=C1)=O.Cl

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for Ro 8-4304 hydrochloride

参考文献 for Ro 8-4304 hydrochloride

参考文献是支持产品生物活性的出版物。

Kew et al (1998) State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist. Br.J.Pharmacol. 123 463 PMID: 9504387

Kew and Kemp (1998) An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J.Physiol. 512 17 PMID: 9729614

按产品操作查看相关产品

查看全部 NMDA Receptor Antagonists

关键词: Ro 8-4304 hydrochloride, Ro 8-4304 hydrochloride supplier, NR2B, selective, antagonists, NMDA, Receptors, Glutamate, Ionotropic, N-Methyl-D-Aspartate, iGluR, Ro8-4304, GluN2B, 3343, Tocris Bioscience

篇 Ro 8-4304 hydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 Ro 8-4304 hydrochloride 的引用文献。

Ro 8-4304 hydrochloride 的评论

目前没有该产品的评论。 Be the first to review Ro 8-4304 hydrochloride and earn rewards!

Have you used Ro 8-4304 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.